Short Interest in Vivos Therapeutics, Inc. (NASDAQ:VVOS) Increases By 37.5%

Vivos Therapeutics, Inc. (NASDAQ:VVOS) was the recipient of a large growth in short interest in the month of November. As of November 15th, there was short interest totalling 130,800 shares, a growth of 37.5% from the October 31st total of 95,100 shares. Currently, 3.0% of the company’s shares are sold short. Based on an average daily volume of 1,360,000 shares, the short-interest ratio is currently 0.1 days.

Vivos Therapeutics Stock Performance

Shares of VVOS opened at $3.41 on Friday. The firm has a market cap of $16.50 million, a PE ratio of -0.60 and a beta of 7.71. Vivos Therapeutics has a 52-week low of $1.91 and a 52-week high of $31.50. The business’s 50 day moving average price is $2.80 and its two-hundred day moving average price is $2.57.

Analysts Set New Price Targets

Several research firms have recently weighed in on VVOS. Alliance Global Partners decreased their price objective on shares of Vivos Therapeutics from $8.25 to $6.00 and set a “buy” rating for the company in a research report on Tuesday, November 19th. Ascendiant Capital Markets reiterated a “buy” rating and set a $6.60 price target on shares of Vivos Therapeutics in a report on Wednesday, November 20th.

Vivos Therapeutics Company Profile

Vivos Therapeutics, Inc, a medical technology company, develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring.